|
Press Releases |
|
![](/images/company/BioVaxys.jpg) |
|
Tuesday, December 1, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Monday, November 30, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Wednesday, November 11, 2020 |
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
Monday, November 2, 2020 |
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Flexidynamic Sees Significant Turnaround in PBT by 277.62% for Q2 FY2024, Better Prospects Ahead
Sept 1, 2024 08:00 HKT/SGT
|
|
|
GF Securities Announces its 2024 Interim Results
Aug 31, 2024 13:13: JST
|
|
|
GF Securities Announces its 2024 Interim Results
Aug 31, 2024 12:12 HKT/SGT
|
|
|
廣發證券公佈2024年度中期業績
Aug 31, 2024 11:54 HKT/SGT
|
|
|
广发证券公布2024年度中期业绩
Aug 31, 2024 11:47 HKT/SGT
|
|
|
卓悅集團公佈2024年中期業績
Aug 31, 2024 11:19 HKT/SGT
|
|
|
卓悦集团公布2024年中期业绩
Aug 31, 2024 11:11 HKT/SGT
|
|
|
Celeb-red our Nation's Birthday with LAC!
Aug 31, 2024 09:00 HKT/SGT
|
|
|
Gome Retail Continue to Focuses on Main Business, Actively Innovates and Transforms to Reduce Costs and Increase Efficiency
Aug 31, 2024 00:32: JST
|
|
|
Legend Holdings Recorded a Revenue of RMB233.4 Billion in H1 2024
Aug 30, 2024 23:41: JST
|
|
|
Gome Retail Continue to Focuses on Main Business, Actively Innovates and Transforms to Reduce Costs and Increase Efficiency
Aug 30, 2024 23:32 HKT/SGT
|
|
|
國美零售持續聚焦主業 積極創新轉型降本增效
Aug 30, 2024 23:27 HKT/SGT
|
|
|
GVRenting Unveils Sustainable Solutions in Urban Architecture
Aug 30, 2024 23:19: JST
|
|
|
国美零售持续聚焦主业 积极创新转型降本增效
Aug 30, 2024 23:14 HKT/SGT
|
|
|
聯控(3396. HK)半年收入升16% 發展新質生產力應挑戰
Aug 30, 2024 23:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|